Abstract: Sodium-dependent glucose transporter 2 inhibitor (SGLT-2i) is a new type of oral hypoglycemic agent, which can reduce the renal glucose threshold and promote urinary glucose excretion by inhibiting sodium-dependent glucose transporter 2 (SGLT-2), and finally achieve the effect of reducing the level of glucose in blood circulation. At present, about 40% of diabetic patients have chronic kidney disease (CKD), and a large part of them will progress to end-stage renal disease (ESRD). SGLT-2i not only have a good hypoglycemic effect, but also can reduce incidence of adverse cardiovascular events and delay the progression of kidney disease, and the renal benefits can be observed even in non-diabetic patients with CKD. This study summarized the clinical trial results of SGLT-2i in kidney, and explored its possible mechanism of action and adverse reactions.